[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UY32125A - Compuestos novedosos como ligandos de receptores de canabinoides - Google Patents

Compuestos novedosos como ligandos de receptores de canabinoides

Info

Publication number
UY32125A
UY32125A UY0001032125A UY32125A UY32125A UY 32125 A UY32125 A UY 32125A UY 0001032125 A UY0001032125 A UY 0001032125A UY 32125 A UY32125 A UY 32125A UY 32125 A UY32125 A UY 32125A
Authority
UY
Uruguay
Prior art keywords
ligands
canabinoid
receivers
new compounds
compounds
Prior art date
Application number
UY0001032125A
Other languages
English (en)
Inventor
William A Carroll
Michael J Dart
Jennifer M Frost
Steven P Latshaw
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41210849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY32125(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of UY32125A publication Critical patent/UY32125A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38Nitrogen atoms
    • C07D231/40Acylated on said nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/1251,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Ligandos de receptores de canabinoides de la fórmula (I) en donde A1, A5, Rx, X4 y Z son como se definen en la memoria descriptiva. Se divulgan asimismo composiciones que comprenden dichos compuestos y métodos para el tratamiento de condiciones y trastornos usando dichos compuestos y composiciones.
UY0001032125A 2008-09-16 2009-09-16 Compuestos novedosos como ligandos de receptores de canabinoides UY32125A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9737808P 2008-09-16 2008-09-16
US22420009P 2009-07-09 2009-07-09

Publications (1)

Publication Number Publication Date
UY32125A true UY32125A (es) 2010-04-30

Family

ID=41210849

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032125A UY32125A (es) 2008-09-16 2009-09-16 Compuestos novedosos como ligandos de receptores de canabinoides

Country Status (23)

Country Link
US (2) US8188135B2 (es)
EP (3) EP2428507B1 (es)
JP (1) JP2012502917A (es)
KR (1) KR20110061619A (es)
CN (1) CN102216277A (es)
AR (2) AR073599A1 (es)
AU (1) AU2009293319A1 (es)
BR (1) BRPI0919135A2 (es)
CA (1) CA2737199A1 (es)
CL (1) CL2011000544A1 (es)
CO (1) CO6361998A2 (es)
DO (1) DOP2011000081A (es)
EC (1) ECSP11010974A (es)
ES (1) ES2556752T3 (es)
IL (1) IL211406A0 (es)
MX (1) MX2011002811A (es)
PA (1) PA8842501A1 (es)
PE (1) PE20110804A1 (es)
RU (1) RU2011115087A (es)
TW (1) TW201016692A (es)
UY (1) UY32125A (es)
WO (1) WO2010033543A2 (es)
ZA (1) ZA201101590B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841334B2 (en) * 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
EP2038266A2 (en) * 2006-05-31 2009-03-25 Abbott Laboratories Compounds as cannabinoid receptor ligands and uses thereof
CA2647598A1 (en) * 2006-05-31 2007-12-06 Abbott Laboratories Compounds as cannabinoid receptor ligands and uses thereof
WO2008121558A1 (en) 2007-03-28 2008-10-09 Abbott Laboratories 1, 3-thiazol-2 (3h) -ylidene compounds as cannabinoid receptor ligands
US7872033B2 (en) * 2007-04-17 2011-01-18 Abbott Laboratories Compounds as cannabinoid receptor ligands
MX2009012374A (es) * 2007-05-18 2009-12-01 Abbott Lab Compuestos novedosos como ligandos del receptor de canabinoides.
US9193713B2 (en) * 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
CN102036984A (zh) 2008-03-11 2011-04-27 雅培制药有限公司 作为大麻素受体配体的新化合物
US8846730B2 (en) * 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
US8188135B2 (en) * 2008-09-16 2012-05-29 Abbott Laboratories Compounds as cannabinoid receptor ligands
PA8854001A1 (es) * 2008-12-16 2010-07-27 Abbott Lab Compuestos novedosos como ligandos de receptores de canabinoides
WO2010111574A1 (en) * 2009-03-27 2010-09-30 Abbott Laboratories Compounds as cannabinoid receptor ligands
WO2011159785A1 (en) 2010-06-15 2011-12-22 Abbott Laboratories Novel compounds as cannabinoid receptor ligands
CN103396376B (zh) * 2013-07-31 2016-08-10 杨文茂 一种抗菌抗癌活性化合物
JP6616785B2 (ja) * 2014-05-19 2019-12-04 シンジェンタ パーティシペーションズ アーゲー 硫黄置換フェニル基またはピリジン基を有する殺虫的に活性なアミド誘導体
EP3212241B1 (en) * 2014-10-27 2019-05-08 F. Hoffmann-La Roche AG Radiolabeled cannabinoid receptor 2 ligand
CN106749078B (zh) * 2015-11-23 2019-01-04 中国科学院大连化学物理研究所 一种2-亚胺基恶唑的合成方法

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1522361A1 (de) 1966-03-08 1969-07-24 Agfa Gevaert Ag Sensibilisierung lichtempfindlicher Polymerer
US3557142A (en) * 1968-02-20 1971-01-19 Sterling Drug Inc 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
DE1772867A1 (de) 1968-07-15 1971-06-16 Agfa Gevaert Ag Sensibilisierung von Schichten aus lichtvernetzbaren Polymeren
JPS5089367A (es) 1973-12-14 1975-07-17
JPS57171986A (en) 1981-04-14 1982-10-22 Taiho Yakuhin Kogyo Kk Heterocylic ring compound containing sulfur
DE3333450A1 (de) * 1983-09-16 1985-04-11 Hoechst Ag, 6230 Frankfurt Trihalogenmethylgruppen enthaltende carbonylmethylenheterocyclen, verfahren zu ihrer herstellung und lichtempfindliches gemisch, das diese verbindungen enthaelt
US4978664A (en) * 1984-08-06 1990-12-18 Sterling Drug Inc. 3-arylcarbonyl- and 3-cycloalkyl-carbonyl-1-aminoalkyl-1H-indole pharmaceutical compositions
US4885295A (en) * 1984-08-06 1989-12-05 Sterling Drug Inc. Method of use of 3-arylcarbonyl- and 3-cycloalkyl-carbonyl-1-aminoalkyl-1H-indoles
DE3533331A1 (de) 1985-09-18 1987-03-26 Heumann Ludwig & Co Gmbh Pyridothiazolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3807381A1 (de) * 1988-03-07 1989-09-21 Hoechst Ag 4,6-bis-trichlormethyl-s-triazin-2-ylgruppen enthaltende heterocyclische verbindungen, verfahren zu ihrer herstellung und lichtempfindliches gemisch, das diese verbindung enthaelt
TW205041B (es) 1989-08-07 1993-05-01 Fujisawa Pharmaceutical Co
DE4021439A1 (de) * 1989-12-14 1991-06-20 Bayer Ag 2-iminopyridin-derivate
US6559186B1 (en) * 1990-02-26 2003-05-06 Arc 1, Inc. Compositions and methods of treatment of sympathetically maintained pain
US5013837A (en) * 1990-03-08 1991-05-07 Sterling Drug Inc. 3-Arylcarbonyl-1H-indole-containing compounds
US4973587A (en) * 1990-03-08 1990-11-27 Sterling Drug Inc. 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method
WO1992015564A1 (en) 1991-03-11 1992-09-17 Nippon Soda Co., Ltd. Novel heterocyclic compound
CA2131191A1 (en) * 1992-03-03 1993-09-04 Mitsuru Shibata Pyrazole derivatives
DE69319956T2 (de) 1992-04-30 1999-01-14 Hodogaya Chemical Co., Ltd., Tokio/Tokyo Benzothiazolederivate und diese enthaltende fungizide Zusammensetzungen für Landwirtschaft und Gartenbau
US5654322A (en) * 1992-08-11 1997-08-05 Wakunaga Seiyaku Kabushiki Kaisha Biphenylmethane derivatives and pharmaceuticals containing the same
US5530019A (en) * 1993-04-05 1996-06-25 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives useful as testosterone 5α-reductase inhibitors
US5395836A (en) 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
JPH06345736A (ja) 1993-06-14 1994-12-20 Tokuyama Soda Co Ltd ウレタン化合物を製造する方法
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
JPH10503171A (ja) 1994-05-17 1998-03-24 ダウエランコ N−(5−イソチアゾリル)アミド有害生物防除剤
CA2194671A1 (en) 1994-07-08 1996-01-25 Ev3 Inc. Method of forming medical devices; intravascular occlusion devices
FR2735774B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
DK1019385T3 (da) 1995-09-15 2004-05-24 Upjohn Co Aminoaryloxazolidinon-N-oxider
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
US6323214B1 (en) * 1997-10-29 2001-11-27 Medco Research, Inc Allosteric adenosine receptor modulators
US6358992B1 (en) * 1998-11-25 2002-03-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with indole derivatives
EP1171437B1 (en) 1999-04-20 2003-10-08 Syngenta Limited Pesticidal indazole or benzotriazole derivatives
DE19928033A1 (de) 1999-06-18 2000-12-21 Basf Ag Verwendung von cyclischen Enaminen als Lichtschutzmittel
FR2796643B1 (fr) 1999-07-22 2005-04-29 Sod Conseils Rech Applic Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique
GB9918037D0 (en) * 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
EP1206474B1 (en) 1999-08-27 2004-05-26 Abbott Laboratories Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors
JP3936189B2 (ja) 1999-09-14 2007-06-27 塩野義製薬株式会社 2−イミノ−1,3−チアジン誘導体
EP1223929B1 (en) 1999-10-18 2006-08-23 The University Of Connecticut Cannabimimetic indole derivatives
GB0002032D0 (en) 2000-01-28 2000-03-22 Zeneca Ltd Chemical compounds
GB0002034D0 (en) 2000-01-28 2000-03-22 Zeneca Ltd Chemical compounds
GB0006289D0 (en) * 2000-03-15 2000-05-03 Smithkline Beecham Plc New use
GB0010437D0 (en) 2000-04-28 2000-06-14 Darwin Discovery Ltd Process
KR100758775B1 (ko) 2000-06-30 2007-09-14 다이닛본 스미토모 세이야꾸 가부시끼가이샤 5원환 화합물
US6369052B1 (en) * 2000-08-07 2002-04-09 Georgetown University Combination of huperzine and nicotinic compounds as a neuroprotective agent
FR2816938B1 (fr) 2000-11-22 2003-01-03 Sanofi Synthelabo Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
ATE478670T1 (de) 2001-01-29 2010-09-15 Univ Connecticut Rezeptor-selektive cannabimimetische aminoalkylindole
US20030008807A1 (en) 2001-06-14 2003-01-09 The Regents Of The University Of California Novel signaling pathway for the production of inflammatory pain and neuropathy
US7949668B2 (en) * 2001-08-20 2011-05-24 Pardalis, Inc. Common point authoring system for the complex sharing of hierarchically authored data objects in a distribution chain
US20040259912A1 (en) * 2001-09-28 2004-12-23 Takahiro Matsumoto Benzine derivatives, process for preparing the same and use thereof
US7183288B2 (en) * 2001-11-01 2007-02-27 Herwig Josephus Margareta Janssen, legal representative Amide derivatives as glycogen synthase kinase 3-β inhibitors
US6727247B2 (en) 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives
ES2270080T3 (es) * 2002-05-16 2007-04-01 Bayer Cropscience Gmbh Derivados de piridincarboxamida pesticidas.
JP3902523B2 (ja) * 2002-08-05 2007-04-11 富士フイルム株式会社 光情報記録媒体および情報記録方法
US20040077617A1 (en) * 2002-10-22 2004-04-22 Bennani Youssef L. Fused cycloalkyl amides and acids and their therapeutic applications
FR2847899B1 (fr) 2002-11-29 2006-04-28 Sanofi Synthelabo Derives d'indole-3-carboxamide, leur preparation et leur application en therapeutique
US7390670B2 (en) * 2003-02-20 2008-06-24 Lumigen, Inc. Signalling compounds and methods for detecting hydrogen peroxide
US20040259887A1 (en) 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
WO2005000825A1 (ja) 2003-06-27 2005-01-06 Dainippon Sumitomo Pharma Co., Ltd. チアゾールイミン類およびオキサゾールイミン類
US6964237B2 (en) 2003-06-30 2005-11-15 Mark P. Hepp Grate block for a refuse incineration grate
US20070275962A1 (en) 2003-09-10 2007-11-29 Gpc Biotech Ag Heterobicyclic Compounds as Pharmaceutically Active Agents
ES2298840T3 (es) 2003-12-08 2008-05-16 F. Hoffmann-La Roche Ag Derivados de tiazol.
GB0402357D0 (en) 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
WO2005099353A2 (en) 2004-04-19 2005-10-27 Symed Labs Limited A novel process for the preparation of linezolid and related compounds
SE0401342D0 (sv) 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds
SE0401345D0 (sv) 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine as scaffold
WO2006008754A1 (en) 2004-07-20 2006-01-26 Symed Labs Limited Novel intermediates for linezolid and related compounds
WO2006039164A2 (en) * 2004-09-29 2006-04-13 Amr Technology, Inc. Novel cyclosporin analogues and their pharmaceutical uses
WO2006051704A1 (ja) 2004-11-15 2006-05-18 Taisho Pharmaceutical Co., Ltd. イミン化合物
MX2007007573A (es) * 2004-12-21 2007-07-24 Abbott Lab Indoles de 3-cicloalquilcarbonilo en la forma de ligandos de receptor canabinoide.
FR2880023B1 (fr) 2004-12-23 2007-02-23 Sanofi Aventis Sa Derives de n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine leur preparation et leur application en therapeutique
US7759337B2 (en) * 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
TW200700387A (en) 2005-03-21 2007-01-01 Akzo Nobel Nv 1-benzylindole-2-carboxamide derivatives
US7674912B2 (en) * 2005-04-25 2010-03-09 H. Lundbeck A/S Pro-drugs of N-thiazol-2-yl-benzamide derivatives
US20070155738A1 (en) * 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
WO2007046550A1 (en) * 2005-10-21 2007-04-26 Mitsubishi Tanabe Pharma Corporation Pyrazole compounds having cannabinoid receptor (cb1) antagonizing activity
AR057987A1 (es) 2005-11-24 2008-01-09 Astrazeneca Ab Compuestos agonistas de cb1 (receptor cannabinoide)
KR100778673B1 (ko) 2005-12-26 2007-11-22 주식회사 포스코 용철 제조 장치
CA2647598A1 (en) 2006-05-31 2007-12-06 Abbott Laboratories Compounds as cannabinoid receptor ligands and uses thereof
EP2038266A2 (en) * 2006-05-31 2009-03-25 Abbott Laboratories Compounds as cannabinoid receptor ligands and uses thereof
US8841334B2 (en) * 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
CN101479262A (zh) * 2006-06-27 2009-07-08 艾博特公司 噻唑啉和唑啉衍生物及其应用方法
CN101547910A (zh) * 2006-07-28 2009-09-30 合成纤维有限公司 结晶埃罗替尼
US7868038B2 (en) * 2006-08-31 2011-01-11 Abbott Laboratories Compounds as cannabinoid receptor ligands
US7985768B2 (en) * 2006-08-31 2011-07-26 Abbott Laboratories Compounds as cannabinoid receptor ligands
WO2008063781A2 (en) 2006-10-12 2008-05-29 Abbott Laboratories Chemical compounds as cannabinoid receptor ligands
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
US7793912B2 (en) * 2006-11-08 2010-09-14 Denso Corporation Fluid pressure actuated poppet valve
US9763894B2 (en) * 2006-12-05 2017-09-19 Virginia Commonwealth University Inflammation therapy
TW200831092A (en) * 2006-12-21 2008-08-01 Astrazeneca Ab Therapeutic agents
WO2008079687A1 (en) * 2006-12-22 2008-07-03 Abbott Laboratories Novel compounds as cannabinoid receptor ligands and uses thereof
EP2121641B1 (en) 2007-02-15 2014-09-24 F. Hoffmann-La Roche AG 2-aminooxazolines as taar1 ligands
WO2008121558A1 (en) 2007-03-28 2008-10-09 Abbott Laboratories 1, 3-thiazol-2 (3h) -ylidene compounds as cannabinoid receptor ligands
US7872033B2 (en) 2007-04-17 2011-01-18 Abbott Laboratories Compounds as cannabinoid receptor ligands
US8501794B2 (en) * 2007-04-17 2013-08-06 Abbvie Inc. Compounds as cannabinoid receptor ligands
KR20100105802A (ko) * 2007-04-19 2010-09-29 콘서트 파마슈티컬즈, 인크. 중수소화된 모르폴리닐 화합물
MX2009012374A (es) 2007-05-18 2009-12-01 Abbott Lab Compuestos novedosos como ligandos del receptor de canabinoides.
US7531685B2 (en) * 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090088416A1 (en) * 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090082471A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090137457A1 (en) 2007-10-02 2009-05-28 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
US9193713B2 (en) * 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
US20090105338A1 (en) * 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
US8410124B2 (en) 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
US8044071B2 (en) * 2007-10-18 2011-10-25 Abbott Laboratories Method for reducing side effects of CB2 receptor agonist therapy using a combination of a selective CB2 receptor agonist and a selective CB1 receptor antagonist
EP2217548A1 (en) * 2007-10-26 2010-08-18 Concert Pharmaceuticals Inc. Deuterated darunavir
JP2011504186A (ja) 2007-11-21 2011-02-03 アボット・ラボラトリーズ カンナビノイド受容体リガンドとしての新規な化合物およびその使用
CN102036984A (zh) * 2008-03-11 2011-04-27 雅培制药有限公司 作为大麻素受体配体的新化合物
US8173687B2 (en) * 2008-08-15 2012-05-08 Abbott Laboratories Compounds as cannabinoid receptor ligands
US8846730B2 (en) * 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
US8188135B2 (en) * 2008-09-16 2012-05-29 Abbott Laboratories Compounds as cannabinoid receptor ligands
MX2011004749A (es) 2008-11-04 2011-06-01 Abbott Lab Nuevos compuestos como ligandos del receptor de canabinoide.
PA8854001A1 (es) 2008-12-16 2010-07-27 Abbott Lab Compuestos novedosos como ligandos de receptores de canabinoides
US8288428B2 (en) * 2009-03-27 2012-10-16 Abbott Laboratories Compounds as cannabinoid receptor ligands
CN102448957A (zh) * 2009-03-27 2012-05-09 雅培制药有限公司 作为大麻素受体配体的化合物
WO2010111574A1 (en) 2009-03-27 2010-09-30 Abbott Laboratories Compounds as cannabinoid receptor ligands
WO2011159785A1 (en) * 2010-06-15 2011-12-22 Abbott Laboratories Novel compounds as cannabinoid receptor ligands

Also Published As

Publication number Publication date
RU2011115087A (ru) 2012-10-27
ECSP11010974A (es) 2011-05-31
PA8842501A1 (es) 2010-04-21
AU2009293319A1 (en) 2010-03-25
DOP2011000081A (es) 2011-07-15
TW201016692A (en) 2010-05-01
US8188135B2 (en) 2012-05-29
AR077664A2 (es) 2011-09-14
CN102216277A (zh) 2011-10-12
US8859596B2 (en) 2014-10-14
KR20110061619A (ko) 2011-06-09
ZA201101590B (en) 2012-08-29
CA2737199A1 (en) 2010-03-25
US20100069349A1 (en) 2010-03-18
EP2896615A1 (en) 2015-07-22
US20100069348A1 (en) 2010-03-18
EP2334646A2 (en) 2011-06-22
MX2011002811A (es) 2011-04-12
CL2011000544A1 (es) 2011-06-17
WO2010033543A2 (en) 2010-03-25
JP2012502917A (ja) 2012-02-02
EP2428507B1 (en) 2015-10-21
BRPI0919135A2 (pt) 2015-12-08
PE20110804A1 (es) 2011-11-30
AR073599A1 (es) 2010-11-17
ES2556752T3 (es) 2016-01-20
CO6361998A2 (es) 2012-01-20
EP2428507A3 (en) 2012-06-13
EP2428507A2 (en) 2012-03-14
IL211406A0 (en) 2011-05-31
WO2010033543A3 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
UY32125A (es) Compuestos novedosos como ligandos de receptores de canabinoides
UY32331A (es) Compuestos novedosos como ligandos de receptores de canabinoides
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
TN2011000279A1 (en) Novel pyrazole -4-n-alkoxycarboxamides as microbiocides
GEP20146072B (en) New compounds
CL2008001897A1 (es) Proceso para la preparacion de 3-halometil-1-metil-1h-pirazol, utiles como intermediario en la produccion de fungicidas; compuestos derivados de 3-halometil-1-metil-1h-pirazol.
CO6382157A2 (es) Compuestos pirazina como inhibidores de fosfodiesterasa 10
CO6630189A2 (es) Compuestos heterocíclicos de nitrógeno útiles como inhibidores de pde10
UA103625C2 (en) 5-hetrocyclylalkyl-3-hydroxy-2-phenylcyclopent-2-enons as herbicides
TW200942535A (en) Novel compounds as cannabinoid receptor ligands
MA32505B1 (fr) 5-alcynyl-pyrimidines
MX2010001093A (es) Herbicidas novedosos.
UA106880C2 (uk) Нові гербіциди
CO6341625A2 (es) Derivados de indol como agentes anticáncer
TN2009000536A1 (en) Novel herbicides
ECSP11011217A (es) Microbiocidas nuevos.
CR20110023A (es) Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida
IN2012DN01223A (es)
CR20110170A (es) Compuestos novedosos como ligandos de receptores de canabinoides
ZA200705490B (en) Substituted benzimidazoles for treatment of histomoniasis
MA33932B1 (fr) Dérivés de 2-aldoximino-5-fluoropyrimidine
MX2010003926A (es) Compuestos novedosos como ligandos del receptor de canabinoides.
UA101427C2 (en) Novel microbiocides
CL2010000415A1 (es) Compuestos derivados de fenil-etilen-octahidro-indol, antagonista mglur5; utiles en el tratamiento de enfermedades del snc (divisional de la solicitud cl 2764-02).

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181114